Roivant Sciences Ltd [ROIV] stock is trading at $22.98, down -0.65%. An important factor to consider is whether the stock is rising or falling in short-term value. The ROIV shares have gain 3.70% over the last week, with a monthly amount glided 1.23%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Roivant Sciences Ltd [NASDAQ: ROIV] stock has seen the most recent analyst activity on September 02, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $16. On February 15, 2024, Wolfe Research initiated with a Outperform rating and assigned a price target of $17 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $20 on January 05, 2024. Deutsche Bank initiated its recommendation with a Buy and recommended $14 as its price target on December 12, 2023. Guggenheim started tracking with a Buy rating for this stock on October 17, 2023, and assigned it a price target of $17. In a note dated June 08, 2023, BofA Securities initiated an Neutral rating and provided a target price of $10.50 on this stock.
Roivant Sciences Ltd [ROIV] stock has fluctuated between $8.73 and $23.91 over the past year. Currently, Wall Street analysts expect the stock to reach $26.5 within the next 12 months. Roivant Sciences Ltd [NASDAQ: ROIV] shares were valued at $22.98 at the most recent close of the market. An investor can expect a potential return of 15.32% based on the average ROIV price forecast.
Analyzing the ROIV fundamentals
Roivant Sciences Ltd [NASDAQ:ROIV] reported sales of 20.33M for the trailing twelve months, which represents a drop of -64.89%. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -56.59%, Pretax Profit Margin comes in at -42.59%, and Net Profit Margin reading is -18.4%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.08 and Total Capital is -0.23. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Roivant Sciences Ltd’s Current Ratio is 33.70. On the other hand, the Quick Ratio is 33.70, and the Cash Ratio is 9.24. Considering the valuation of this stock, the price to sales ratio is 786.15, the price to book ratio is 3.63.
Transactions by insiders
Recent insider trading involved Venker Eric, President & Immunovant CEO, that happened on Jan 12 ’26 when 0.2 million shares were sold. Officer, Venker Eric completed a deal on Jan 12 ’26 to buy 0.2 million shares. Meanwhile, President & CIO Sukhatme Mayukh sold 1.02 million shares on Dec 31 ’25.
